Background It is unclear whether there is a difference in the effect of gefitinib treatment
between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and …

Background The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib
is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene …

Background: It is unclear whether there is a difference in the efficacy of treatment by
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) between patients …

Abstract Background and Objectives: The association between epidermal growth factor
receptor (EGFR) mutations and response to EGFR tyrosine kinase inhibitor (TKI) has been …

AIMS: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small
cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse …

BACKGROUND: Patients with lung adenocarcinoma who carry epidermal growth factor
receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor …

Purpose To evaluate the relationship between mutations of the epidermal growth factor
receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent …

Gefitinib is the first approved epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer …

The aim of this study was to investigate whether the pattern of epidermal growth factor
receptor (EGFR) gene mutations affects sensitivity to gefitinib treatment. We investigated 44 …

OBJECTIVES The impact of epidermal growth factor receptor (EGFR) status and the use of
EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in …